Overview

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.
Phase:
Phase 3
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Lenalidomide